Semaglutide — effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP

Overweight and obesity are a worldwide common problem and are diagnosed with a body mass index (BMI) value in the range of 25.0–29.9 kg/m² and ≥30.0 kg/m², respectively. Obese patients are at high risk of developing concomitant diseases, such as hypertension, type 2 diabetes mellitus (DM2), hyperlipidemia, stroke and even some types of cancer. In the Russian Federation in 2016, the proportion of overweight people was 62.0%, with obesity — 26.2%. The authors performed an electronic search in the PubMed information database. Two search elements were used: «Semaglutide» and «Obesity». The search included studies published from the date of foundation of the database to August 2022. The search was limited only to the results of clinical trials. The authors obtained 26 results, but only the studies of SUSTAIN, PIONEER (Peptide Innovation for Early Diabetes Treatment) and STEP were considered, since they were original, randomized, controlled clinical trials conducted before the approval of semaglutide for the treatment of DM2 and obesity.

1. Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. AM J Health-Syst Pharm. 2016;73(19):1493-1507. doi: https://doi.org/10.2146/ajhp150990

2. World Health Organization. Obesity and overweight. 2020 [cited 21.05.2023]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

3. Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-325 (In Russ.). doi: https://doi.org/10.26442/20751753.2021.4.200832

4. Troshina EA, Ershova EV. Pharmacotherapy of obesity: what’s new? Problems of Endocrinology. 2018;64(4):270-276 (In Russ.). doi: https://doi.org/10.14341/probl9315

5. Matheus ASDM, Tannus LRM, Cobas RA, et al. Impact of diabetes on cardiovascular disease: An update. Int J Hypertens. 2013;2013:1-15. doi: https://doi.org/10.1155/2013/653789

6. U. S. Food and Drug Administration. FDA requests the withdrawal of weight-loss drug Belviq, Belviq XR (Lorcaserin) from the market: potential risk of cancer outweighs the benefits. Washington, DC: Center for Drug Evaluation and Research; 2020.

7. U. S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. Washington, DC: Center for Drug Evaluation and Research; 2021.

8. Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi: https://doi.org/10.1111/dom.12932

9. Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341-354. doi: https://doi.org/10.1016/S2213-8587(17)30092-X

10. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258-266. doi: https://doi.org/10.2337/dc17-0417

11. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi: https://doi.org/10.1056/NEJMoa2032183

12. Davies M, Færch L, Jeppesen OK. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;397(10278):971-984. doi: https://doi.org/10.1016/S0140-6736(21)00213-0

13. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. doi: https://doi.org/10.1001/jama.2021.1831

14. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi: https://doi.org/10.1001/jama.2021.3224

15. Garvey WT, Batterham RL, Bhatta M, et al. STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi: https://doi.org/10.1038/s41591-022-02026-4.

16. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: https://doi.org/10.1056/NEJMoa1607141

17. Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021;23(2):404-414. doi: https://doi.org/10.1111/dom.14232

18. Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once-weekly vs sitagliptin once-daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378-388. doi: https://doi.org/10.1111/dom.13082

19. Kohei K, Yuichira Y, Jirotaka W, et al.. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20(5):1202-1212. doi: https://doi.org/10.1111/dom.13218

20. Kaku K, Yamada Y, Watada H, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291-2301. doi: https://doi.org/10.1210/jc.2018-00070

21. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. doi: https://doi.org/10.1016/S2213-8587(17)30013-X

22. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. doi: https://doi.org/10.1016/S2213-8587(19)30066-X

23. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355-366. doi: https://doi.org/10.1016/S2213-8587(17)30085-2

24. Pratley RE, Aroda VR, Lingvay I, et al. SUSTAIN 7 investigators. Semaglutide versus dulaglutide once-weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. doi: https://doi.org/10.1016/S2213-8587(18)30024-X

25. Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834-844. doi: https://doi.org/10.1016/S2213-8587(19)30311-0

26. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100-109. doi: https://doi.org/10.1016/j.diabet.2019.101117

27. Jendle J, Birkenfeld AL, Polonsky WH, et al. Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials. Diabetes Obes Metab. 2019;21(10):2315-2326. doi: https://doi.org/10.1111/dom.13816

28. Rodbard HW, Rosenstock J, Canani LH, et al. PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272-2281. doi: https://doi.org/10.2337/dc19-0883

29. Thethi TK, Pratley R, Efficacy MJJ. Safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263-1277. doi: https://doi.org/10.1111/dom.14054

30. Rosenstock J, Allison D, Birkenfeld AL, et al. PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea. JAMA. 2019;321(15):1466-1480. doi: https://doi.org/10.1001/jama.2019.2942

31. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1 Investigators. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732. doi: https://doi.org/10.2337/dc19-0749

32. Mosenzon O, Blicher TM, Rosenlund S, et al. PIONEER 5 Investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3A trial. Lancet Diabetes Endocrinol. 2019;7(7):515-527. doi: https://doi.org/10.1016/S2213-8587(19)30192-5

33. Pratley R, Amod A, Hoff ST, et al. PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3A trial. Lancet. 2019;394(10192):39-50. doi: https://doi.org/10.1016/S0140-6736(19)31271-1

34. Yamada Y, Katagiri H, Hamamoto Y, et al. PIONEER 9 investigators. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes & Endocrinology. 2020;8(5):377-391. doi: https://doi.org/10.1016/S2213-8587(20)30075-9

35. Zinman B, Aroda VR, Buse JB, et al.. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262-2271. doi: https://doi.org/10.2337/dc19-0898

36. Zinman B, Aroda VR, Buse JB, et al. PIONEER 8 Investigators. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3A trial. Lancet Diabetes Endocrinol. 2019;7(7):528-539. doi: https://doi.org/10.1016/S2213-8587(19)30194-9

37. Yabe D, Nakamura J, Kaneto H, et al. PIONEER 10 Investigators. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3A trial. Lancet Diabetes Endocrinol. 2020;8(8):392-406. doi: https://doi.org/10.1016/S2213-8587(20)30074-7

38. Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381(9):841-851. doi: https://doi.org/10.1056/NEJMoa1901118

39. DeVries JH, Desouza C, Bellary S, et al. Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. Diabetes Obes Metab. 2018;20(10):2426-2434. doi: https://doi.org/10.1111/dom.13396

40. Quante M, Thate-Waschke I, Schofer M. What are the reasons for patient preference? A comparison between oral and subcutaneous administration. Z Orthop Unfall. 2012;150(4):397-403. doi: https://doi.org/10.1055/s-0031-1298347

41. Center for Drug Evaluation and Research. Guidance for industry developing products for weight management, 2007 [cited 21.05.2023]. Available from: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071612.pdf

42. Khera R, Murad MH, Chandar AK. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424-2434. doi: https://doi.org/10.1001/jama.2016.7602

43. Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II). Obesity. 2013;21(3):935-943. doi: https://doi.org/10.1002/oby.20309

44. Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes. 2000;24(3):306-313. doi: https://doi.org/10.1038/sj.ijo.0801128

45. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330-342. doi: https://doi.org/10.1038/oby.2011.330

46. Fidler MC, Sanchez M, Raether B, et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-3077. doi: https://doi.org/10.1210/jc.2011-1256

47. Strizheletsky VV, Gomon YuМ, Spichakova ЕА, et al. Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(3):320-331. (In Russ.). doi: https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.149

48. Hansen G, Jelsing J, Vrang N. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta Pharmacol Sin. 2012;33(2):194-200. doi: https://doi.org/10.1038/aps.2011.168

49. Matveev GA, Golikova TI, Vasilev AA, et al. Comparison of the effects of liraglutide and sibutramine in obese patients. Obesity and metabolism. 2021;18(2):218-228. (In Russ.). doi: https://doi.org/10.14341/omet12498

50. Shamkhalova MS, Shestakova MV. Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials. Diabetes mellitus. 2022;25(3):204-214. (In Russ.). doi: https://doi.org/10.14341/DM12941